NASDAQ: INMInmed Pharmaceuticals Inc Stock
$2.96+0.24 (+8.82%)
Updated Apr 21, 2025
INM Price
$2.96
Fair Value Price
N/A
Market Cap
$3.57M
52 Week Low
$1.72
52 Week High
$15.70
P/E
-0.22x
P/B
0.58x
P/S
0.69x
PEG
N/A
Dividend Yield
N/A
Revenue
$4.83M
Earnings
-$7.91M
Gross Margin
35.4%
Operating Margin
-156.35%
Profit Margin
-163.8%
Debt to Equity
0.38
Operating Cash Flow
-$7M
Beta
1.18
Next Earnings
May 12, 2025
Ex-Dividend
N/A
Next Dividend
N/A
INM Overview
InMed Pharmaceuticals Incorporated develops cannabinoid-based therapies. Its pipeline includes INM-755, a cannabinol topical cream in a second Phase I clinical trial for the treatment of Epidermolysis Bullosa, INM-088, in preclinical studies for the treatment of glaucoma, and INM-405 for the treatment of pain. It is also developing IntegraSyn, an integrated biosynthesis-based manufacturing process for synthesizing pharmaceutical-grade cannabinoids. InMed Pharmaceuticals was incorporated in 1981 and is headquartered in Vancouver, British Columbia, Canada.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine INM's potential to beat the market
- INM doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
INM
RankedUnranked of 462
RankedUnranked of 462
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $2.55 | A | |
| $7.66 | A | |
| $22.02 | A |
Be the first to know about important INM news, forecast changes, insider trades & much more!
INM News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how INM scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
INM is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
INM is good value based on its book value relative to its share price (0.58x), compared to the US Biotechnology industry average (4.04x)
P/B vs Industry Valuation
INM is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more INM due diligence checks available for Premium users.
Valuation
INM fair value
Fair Value of INM stock based on Discounted Cash Flow (DCF)
Price
$2.96
Fair Value
$5.63
Undervalued by
47.44%
INM is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
INM price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.22x
Industry
-184.27x
Market
27.14x
INM price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.58x
Industry
4.04x
INM is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
INM's financial health
Profit margin
Revenue
$1.1M
Net Income
-$2.6M
Profit Margin
-231.6%
INM's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
INM's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$8.5M
Liabilities
$2.3M
Debt to equity
0.38
INM's short-term assets ($5.47M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
INM's short-term assets ($5.47M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
INM's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$2.5M
Investing
$0.0
Financing
$338.5k
INM's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
INM vs Biotech Stocks
Inmed Pharmaceuticals Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.